Combination Therapy in Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
An open label, non-comparative study design is appropriate for this Phase 4 study designed to
assess whether a core therapy of bosentan, either as monotherapy or with the addition of
sildenafil, enables patients with pulmonary arterial hypertension (PAH) to achieve a 6-minute
walk distance (6 MWD) of ≥380 meters after 28 weeks of therapy This design is also
appropriate to pioneer the utility of cardiac MRI in assessing improved functional capacity
in PAH and exploring its correlation with other parameters.